Nebraska Drug Company Partners with KU Med

By  | 

A Nebraska-based drug company is investing $1 million in a partnership with University of Kansas Medical Center.

BioTarget specializes in cancer treatments. It's leasing space for a new research and development facility on the KU Med Center campus in Kansas City, KS

The 1100 square foot facility is scheduled to open in spring 2009. It will be housed in the Kansas City Biotechnology Development Center. The expansion will create 13 new jobs, to be phased in over three years.

The center will work with the KU Cancer Center to develop tests for identifying and characterizing cancer biomarkers.

"This partnership is expected to generate novel diagnostic and delivery systems and accelerate the commercialization of nanomaterials for in vitro and in vivo diagnostics in oncology and other medical fields," Luis Nunez, Chief Science Officer for BioTarget, said in a statement. "We're excited for the change to work with the University of Kansas, and we appreciate the support of the various economic development groups that helped make this project possible."

Financial and technical assistance for the project was provided by the Kansas Bioscience Authority, KU Med Ctr. and the KS Department of Commerce.